New multiple sclerosis drug ‘can cut relapses by nearly 50%’

Patients welcome results for treatment from pharmaceutical firm Roche, which says it could also treat the primary-progressive form of the disease

A new drug for multiple sclerosis can cut relapses by almost 50% more than the current standard treatment, its manufacturer claims, raising the hopes of sufferers of the disease.

The Swiss pharmaceutical giant Roche announced the headline results for its drug, ocrelizumab, but has not published the detailed outcome of its trials.